Altamira Therapeutics Ltd. CYTOF
0.07
0.00
0.00%
as of 24 Sep
- Market cap
- $1.1M
- P/E
- 0.0×
Follow CYTOF
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | — | 0.00 | 0.00 | — | — |
P/S ratio |
— | — | — | — | — | 0.00 | 0.00 | — | — |
P/FCF ratio |
— | — | — | — | — | 0.00 | 0.00 | — | — |
P/Operating CF |
— | — | — | — | — | (53.03) | (13.61) | — | — |
P/B ratio |
— | — | — | — | — | 35.94 | 10.05 | — | — |
Price to Tangible BV |
— | — | — | — | — | 0.00 | 0.00 | — | — |
EV/Sales |
— | — | — | — | — | 0.00 | 0.00 | — | — |
EV/EBITDA |
— | — | — | — | — | 0.00 | 0.00 | — | — |
EV/Operating CF |
— | — | — | — | — | (24.81) | (3.51) | — | — |
EV/FCF |
— | — | — | — | — | (20.66) | (2.85) | — | — |
Quick Ratio |
3.65 | 1.46 | 1.25 | 0.85 | 3.74 | 0.40 | 0.08 | 1.06 | 1.16 |
Current Ratio |
3.76 | 1.52 | 1.33 | 1.04 | 3.83 | 0.77 | 0.14 | 1.38 | 1.32 |
Net Debt/EBITDA |
0.67 | 0.20 | 0.36 | 0.22 | 2.04 | 0.02 | (0.23) | 0.16 | 0.15 |
Debt/Assets |
34.67% | 56.81% | 14.53% | 0.00% | 2.52% | 3.07% | 98.75% | 0.00% | 0.00% |
Debt/Equity |
0.87 | (4.68) | 0.39 | 0.00 | 0.03 | 0.05 | (0.75) | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 |
Operating CF/Net income |
0.96 | 0.99 | 1.15 | 1.27 | 0.59 | 0.79 | 0.33 | 2.98 | 0.72 |
Capex/Depreciation |
(2.50) | (1.25) | (25.08) | (98.01) | (115.39) | (43.58) | (18.02) | 0.00 | (0.81) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (105.24%) | (407.96%) | (1,532.55%) | (136.13%) | (73.00%) | (119.71%) | (1,071.90%) | 829.81% | (118.79%) | |
| (69.89%) | (91.34%) | (83.32%) | (68.87%) | (55.58%) | (88.92%) | (204.28%) | (54.69%) | (95.05%) | |
ROIC |
0.00% | 0.00% | 0.00% | (102.37%) | (54.71%) | (86.90%) | 0.00% | (61.90%) | (76.92%) |
Return on Tangible Assets |
(122.15%) | (428.63%) | (748.37%) | (4,082.57%) | (94.98%) | 1,580.02% | 238.76% | (1,084.16%) | (1,776.08%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5,367.95 | 910.51 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 13,991.70% | 6,437.81% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 10,087.55% | 1,971.46% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.04 | 0.09 | 0.36 | 0.73 | 0.44 | 0.76 | 0.62 | 0.51 | 0.53 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 1,888.13% | 112.14% | 0.00% | 0.00% |
Graham Net Nets |
— | — | — | — | — | (0.01) | (0.12) | — | — |
Graham Number |
— | — | — | — | — | 0.00 | 20.88 | — | — |
Earnings Yield |
— | — | — | — | — | (7.86%) | (52.90%) | — | — |
Free Cash Flow Yield |
— | — | — | — | — | (4.84%) | (37.27%) | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.11 | 7.04 | 0.00 | 0.00 |
Operating CF per Share |
(74,760.75) | (49,343.00) | (6,764.30) | (1,157.26) | (344.40) | (451.94) | (199.98) | (26.09) | (2.16) |
Capex per Share |
(620.25) | (311.00) | (931.90) | (416.19) | (164.63) | (109.94) | (49.35) | 0.00 | (0.04) |
Free Cash Flow per Share |
(75,381.00) | (49,654.00) | (7,696.20) | (1,573.45) | (509.03) | (561.88) | (249.33) | (26.09) | (2.20) |
Cash per Share |
82,346.50 | 30,434.80 | 2,757.00 | 221.21 | 800.58 | 32.53 | 6.58 | 2.09 | 0.35 |
Shareholders Equity per Share |
35,898.00 | (4,395.00) | 1,865.70 | 832.25 | 1,192.45 | 419.94 | (191.50) | 15.63 | 2.32 |
Interest Debt per Share |
0.03 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
35,898.00 | (4,395.00) | 1,865.70 | 832.25 | 1,192.45 | 419.94 | (191.50) | 15.63 | 2.32 |
Free Cash Flow |
(30.15) | (24.83) | (15.39) | (11.49) | (7.64) | (18.60) | (11.34) | (12.81) | (6.22) |
Working Capital |
25.11 | 5.53 | 1.54 | 0.10 | 9.16 | (1.20) | (11.64) | 0.40 | 0.38 |
Capital Expenditures |
(0.25) | (0.16) | (1.86) | (3.04) | (2.47) | (3.64) | (2.25) | — | (0.10) |
Net Current Asset Value |
12.36 | (4.19) | (0.17) | (0.82) | 8.09 | (2.60) | (13.46) | (0.01) | (0.55) |
EV/EBIT |
— | — | — | — | — | 0.00 | 0.00 | — | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 52.06 | 7.01 | — | 0.00 |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (27,219.74%) | (8,679.08%) | 0.00% | 0.00% |
Price to Operating Income |
— | — | — | — | — | 0.00 | 0.00 | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.26 | 0.49 | 2.14 | 0.46 | 0.43 | 0.00 | 0.00 | 0.00 | 1.27 |
Cash ROIC |
(50.59%) | (106.94%) | (126.61%) | (110.73%) | (17.13%) | (95.84%) | 481.06% | (147.22%) | (82.15%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.13 | 0.35 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.06 | 0.08 | 0.14 | 0.02 | 0.02 | 1.01 | 0.33 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.25 | — | — |
Average Days of Payables |
6,873.12 | 3,572.14 | 3,062.05 | 11,118.37 | 13,935.12 | 602.38 | 1,242.35 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 136.71 | 2.94 | — | — |
Average Receivables |
0.48 | 0.27 | 0.29 | 0.33 | 0.21 | 0.56 | 0.91 | 0.44 | 0.22 |
Average Payables |
1.54 | 1.54 | 1.55 | 1.41 | 0.88 | 2.43 | 4.60 | 2.84 | 0.54 |
Average Inventory |
— | — | — | — | — | — | 0.47 | — | — |
Average Assets |
44.54 | 27.16 | 14.11 | 9.69 | 15.74 | 21.40 | 13.61 | 7.87 | 8.90 |
Average Common Equity |
29.58 | 6.08 | 0.77 | 4.90 | 11.98 | 15.89 | 2.59 | (0.52) | 7.12 |
Columns are period end dates